Nektar Therapeutics held its Annual Meeting of Stockholders on May 23, 2025. During the meeting, several proposals were addressed. The election of Diana Brainard and R. Scott Greer to the board of directors was approved. An amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance by 6,000,000 shares was approved. An amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 390,000,000 shares was approved. Additionally, an amendment to the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-40, at the discretion of the Board, was approved.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。